

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

ESTABLISHMENT OF THE NOMINATION COMMITTEE AND APPOINTMENT OF COMMITTEE MEMBERS

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) is pleased to announce that a nomination committee of the Board (the “**Nomination Committee**”) was established on December 23, 2021.

The Board has appointed Ms. Zhong Huijuan, Mr. Lin Guoqiang and Mr. Chan Charles Sheung Wai as members of the Nomination Committee, and Ms. Zhong Huijuan has been appointed as the chairlady of the Nomination Committee. The terms of reference of the Nomination Committee will be posted on the news website of Hong Kong Exchanges and Clearing Limited and the website of the Company.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, December 23, 2021

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.